Welcome to our dedicated page for Halozyme Thrp news (Ticker: HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Thrp stock.
Halozyme Therapeutics, Inc. (HALO) generates news that spans drug delivery technology, clinical applications, strategic collaborations and corporate finance. As a biopharmaceutical company focused on subcutaneous administration of biologics, Halozyme’s announcements often highlight how its ENHANZE and Hypercon platforms are being integrated into partner therapies and new indications.
News items frequently cover collaboration and license agreements with global pharmaceutical and biotechnology companies. Examples include agreements with Takeda to use ENHANZE with vedolizumab and with Merus to develop a subcutaneous formulation of petosemtamab. These stories typically describe upfront payments, potential milestones and royalty structures, as well as the therapeutic areas targeted by ENHANZE-enabled products.
Another major category of HALO news involves regulatory milestones achieved by partner products that incorporate Halozyme technologies. Recent press releases describe U.S. Food and Drug Administration approvals for DARZALEX Faspro and RYBREVANT FASPRO, both co-formulated with ENHANZE, in multiple myeloma and EGFR-mutated non-small cell lung cancer. Such updates provide insight into how Halozyme’s platforms translate into commercial products and expanded indications.
Halozyme also issues updates on intellectual property and legal matters, including patent enforcement actions related to its MDASE portfolio and court decisions affecting subcutaneous formulations of other companies’ drugs. In addition, investors can follow corporate developments such as acquisitions, including the purchase of Elektrofi and its Hypercon technology, board appointments, executive transitions and participation in healthcare conferences.
For investors and industry observers, the HALO news feed offers a way to track the evolution of Halozyme’s partnership base, the progress of ENHANZE- and Hypercon-enabled products, and key events that may influence the company’s royalty outlook and strategic direction.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that CEO Dr. Helen Torley will present virtually at the BofA Securities 2021 Virtual Health Care Conference on May 11, 2021, at 12:30 p.m. ET. Investors can access the presentation via the Halozyme website, and a recording will be available for six months post-event. Halozyme is known for its innovative ENHANZE technology, which enhances drug delivery and has positively impacted over 400,000 patients worldwide through collaborations with major pharmaceutical companies.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will host a webcast for its Q1 2021 financial results on May 10 at 4:30 p.m. ET. CEO Dr. Helen Torley will lead the call, releasing results for the quarter ended March 31, 2021 following market close. The call will be accessible via the Investors section of Halozyme’s corporate website, with registration open until the call starts. Halozyme is known for its innovative ENHANZE® technology, which enhances patient experiences by reducing treatment times for injectable therapies.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced the pricing of a $700 million private offering of convertible senior notes due 2027. The notes will carry a 0.25% annual interest rate and can convert to cash or shares at an initial conversion price of $77.17 per share. The total net proceeds are estimated at $681.9 million, allocated primarily for repurchasing existing convertible notes and shares, as well as general corporate purposes. The offering is expected to close on March 1, 2021.
Halozyme Therapeutics announced a proposed offering of $500 million in convertible senior notes due 2027, subject to market conditions. The notes will be sold to qualified institutional buyers under Rule 144A of the Securities Act. The company may grant a 30-day option for an additional $75 million of notes. Proceeds will be used for repurchasing existing notes and common stock, enhancing shareholder value. The convertible notes will accrue interest and have specific terms for conversion starting from September 1, 2026. This offering could impact the market price of Halozyme's common stock.
Halozyme Therapeutics (NASDAQ: HALO) reported robust financial results for Q4 and the full year 2020, showcasing a transition to profitability. Q4 revenue soared to $121.7 million, a substantial increase from $53.7 million in Q4 2019, driven by new product approvals and increased royalties. The company projects 2021 revenues of $375-$395 million, marking 40%-48% growth year-over-year. Operating income is expected to grow by 49%-63%. Additionally, Halozyme plans to repurchase up to $125 million in common stock. Cash reserves stood at $368 million.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) is set to host a webcast for its fourth-quarter 2020 financial results on February 23, 2021, at 4:30 p.m. ET. The call, led by CEO Dr. Helen Torley, follows the release of financial results for the quarter ending December 31, 2020. Interested parties can register for the call via the provided link, with a recording available post-event. Halozyme specializes in enhancing patient treatment experiences through its innovative ENHANZE® technology, which shortens drug administration times, and collaborates with various pharmaceutical companies to further develop this technology.
Halozyme Therapeutics (NASDAQ: HALO) announced FDA approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for treating newly diagnosed light chain (AL) amyloidosis. This marks it as the first FDA-approved treatment for this rare blood disorder, which affects around 4,500 U.S. patients annually. The approval follows positive results from the Phase 3 ANDROMEDA study, where DARZALEX FASPRO® showed a hematologic complete response rate of 42%, significantly higher than the 13% seen with standard treatment (VCd). Continued approval is contingent on further clinical trials.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) has provided its 2021 financial guidance, forecasting revenues between $375 million and $395 million, reflecting a growth of approximately 40% to 45% over 2020. The expected GAAP earnings per share range is $1.40 to $1.55, indicating a 55% to 70% increase compared to the previous year. Key growth drivers include the adoption of subcutaneous DARZALEX® and Phesgo®, alongside ongoing collaborations in ENHANZE® drug development.
Halozyme Therapeutics (NASDAQ: HALO) will have Dr. Helen Torley present virtually at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 12:40 p.m. PT. The conference is scheduled from January 11-14, 2021. An audio link to the presentation will be available on Halozyme's website, and a recording will be accessible for 30 days post-event. Halozyme specializes in biopharmaceutical innovations, particularly the ENHANZE® technology, which streamlines drug delivery and enhances patient experiences.
FAQ
What is the current stock price of Halozyme Thrp (HALO)?
What is the market cap of Halozyme Thrp (HALO)?
